Avant Immunotherapeutics Newswire

Avant Immunotherapeutics Newswire

Comprehensive Real-Time News Feed for Avant Immunotherapeutics.

Results 1 - 20 of 269 in Avant Immunotherapeutics

  1. Celldex Therapeutics, Inc. (CLDX) Shares Gap Down to $2.66Read the original story w/Photo

    Friday Sep 15 | IntersportsWire

    Shares of Celldex Therapeutics, Inc. gapped down before the market opened on Wednesday . The stock had previously closed at $2.78, but opened at $2.66.

    Comment?

  2. Celldex Therapeutics, Inc. (CLDX) Shares Gap Down to $2.66Read the original story w/Photo

    Wednesday Sep 13 | The Breeze

    Celldex Therapeutics, Inc. 's share price gapped down prior to trading on Wednesday . The stock had previously closed at $2.78, but opened at $2.66.

    Comment?

  3. Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by BrokeragesRead the original story w/Photo

    Wednesday Sep 13 | AmericanBankingNews.com

    Shares of Celldex Therapeutics, Inc. have received an average recommendation of "Hold" from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company.

    Comment?

  4. 12 Biggest Mid-Day Losers For WednesdayRead the original story

    Wednesday Sep 13 | Benzinga

    Applied Genetic Technologies Corp shares dipped 16.7 percent to $4.12 after the company reported weaker-than-expected Q4 results. A-Mark Precious Metals Inc shares dropped 8.5 percent to $17.12 as the company reported weaker-than-expected results for its fourth quarter on Tuesday.

    Comment?

  5. Celldex Announces Departure Of Chief Medical OfficerRead the original story

    Tuesday Sep 12 | BioSpace

    Celldex Therapeutics, Inc. announced today the resignation of Thomas Davis, M.D., Executive Vice President and Chief Medical Officer of Celldex, effective September 29, 2017. "Celldex's clinical programs have matured greatly during Tom's tenure.

    Comment?

  6. Celldex Therapeutics, Inc. (CLDX) Trading Down 3.5%Read the original story w/Photo

    Monday Sep 11 | Daily Political

    Celldex Therapeutics, Inc. 's share price dropped 3.5% during trading on Monday . The stock traded as low as $2.58 and last traded at $2.69.

    Comment?

  7. BB&T Securities LLC Takes Position in Celldex Therapeutics, Inc.Read the original story w/Photo

    Sunday Sep 10 | IntersportsWire

    BB&T Securities LLC acquired a new position in shares of Celldex Therapeutics, Inc. during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 47,650 shares of the biopharmaceutical company's stock, valued at approximately $117,000.

    Comment?

  8. Celldex Therapeutics, Inc. (CLDX) Sees Strong Trading VolumeRead the original story w/Photo

    Friday Sep 8 | Daily Political

    Celldex Therapeutics, Inc. saw unusually-high trading volume on Friday . Approximately 832,475 shares were traded during mid-day trading, a decline of 42% from the previous session's volume of 1,432,870 shares.The stock last traded at $2.64 and had previously closed at $2.76.

    Comment?

  9. Financial Analysis: Celldex TherapeuticsRead the original story w/Photo

    Tuesday Sep 5 | IntersportsWire

    Celldex Therapeutics and OncoSec Medical are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk. 56.7% of Celldex Therapeutics shares are owned by institutional investors.

    Comment?

  10. State of Wisconsin Investment Board Boosts Holdings in Celldex Therapeutics, Inc.Read the original story w/Photo

    Tuesday Sep 5 | Daily Political

    State of Wisconsin Investment Board raised its position in shares of Celldex Therapeutics, Inc. by 11.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 835,000 shares of the biopharmaceutical company's stock after acquiring an additional 85,000 shares during the quarter.

    Comment?

  11. Zacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will...Read the original story w/Photo

    Tuesday Sep 5 | AmericanBankingNews.com

    Analysts expect that Celldex Therapeutics, Inc. will report $1.17 million in sales for the current quarter, according to Zacks Investment Research . Two analysts have provided estimates for Celldex Therapeutics' earnings, with the highest sales estimate coming in at $1.55 million and the lowest estimate coming in at $790,000.00.

    Comment?

  12. Celldex Therapeutics, Inc. (CLDX) Cut to "Strong Sell" at ValuEngineRead the original story w/Photo

    Sunday Sep 3 | AmericanBankingNews.com

    Several other equities analysts have also recently weighed in on the stock. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the company a "buy" rating in a research report on Wednesday, August 9th.

    Comment?

  13. Canada Pension Plan Investment Board Increases Stake in Celldex Therapeutics, Inc.Read the original story w/Photo

    Thursday Aug 31 | Daily Political

    Canada Pension Plan Investment Board boosted its position in Celldex Therapeutics, Inc. by 9.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 223,600 shares of the biopharmaceutical company's stock after buying an additional 19,800 shares during the period.

    Comment?

  14. Celldex Therapeutics (CLDX) versus OncoSec Medical (ONCS) Head-To-Head ReviewRead the original story w/Photo

    Tuesday Aug 29 | Daily Political

    Celldex Therapeutics and OncoSec Medical are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings. 56.7% of Celldex Therapeutics shares are owned by institutional investors.

    Comment?

  15. 3 Top Healthcare Stocks to Buy NowRead the original story w/Photo

    Thursday Aug 24 | Fox News

    It's been a good year for healthcare stocks in general, but a handful of quality companies haven't been swept upward with the rest of the sector. Allergan plc are both poised to continue churning out profits and dividends for years to come, but they aren't priced that way.

    Comment?

  16. Celldex Announces Completion Of Enrollment In Phase IIb Study Of...Read the original story

    Tuesday Aug 22 | BioSpace

    Celldex Therapeutics, Inc. announced today that patient enrollment has been completed in the Company's Phase 2b METRIC study of glembatumumab vedotin in patients with metastatic triple negative breast cancers that overexpress gpNMB. Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer.

    Comment?

  17. Celldex Announces Completion of Enrollment in Phase 2b Study of...Read the original story

    Wednesday Aug 23 | PressReleasePoint

    Celldex Therapeutics, Inc. announced today that patient enrollment has been completed in the Company's Phase 2b METRIC study of glembatumumab vedotin in patients with metastatic triple negative breast cancers that overexpress gpNMB. Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer.

    Comment?

  18. Reviewing Celldex TherapeuticsRead the original story w/Photo

    Tuesday Aug 22 | IntersportsWire

    Celldex Therapeutics and Blueprint Medicines Corporation are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Celldex Therapeutics presently has a consensus target price of $8.08, suggesting a potential upside of 246.92%.

    Comment?

  19. Celldex Therapeutics, Inc. (CLDX) Position Reduced by Tiaa Cref Investment Management LLCRead the original story w/Photo

    Aug 20, 2017 | Daily Political

    TIAA CREF Investment Management LLC reduced its position in shares of Celldex Therapeutics, Inc. by 7.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 256,576 shares of the biopharmaceutical company's stock after selling 21,532 shares during the period.

    Comment?

  20. Celldex Therapeutics, Inc. (CLDX) Receives Average Recommendation of...Read the original story w/Photo

    Aug 19, 2017 | Daily Political

    Shares of Celldex Therapeutics, Inc. have been given a consensus recommendation of "Hold" by the eleven ratings firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company.

    Comment?